Provention Bio, Inc. Common Stock (PRVB)

PRVB was delisted on the 26th of April, 2023.

• Market cap: $2.37B
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-101.

Employees: 174